Aerie Pharmaceuticals Inc


Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc and Ramot at Tel Aviv University Enter Research Collaboration

Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with …

Stock Update (NASDAQ:AERI): Aerie Pharmaceuticals Inc and GrayBug Announce Research Collaboration

Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with …

Canaccord Genuity Hikes Aerie Pharmaceuticals (AERI) Price Target; Upgrades to Buy

Canaccord Genuity analyst Corey Davis came out with a favorable report on Aerie Pharmaceuticals Inc (NASDAQ:AERI) after the FDA allowed ROCKET 2’s primary endpoint …

Aerie Pharmaceuticals Inc is Up on Primary Endpoint Revision

Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 50% on the news that the FDA has agreed to the company’s proposed change in the primary …

Analyst Reviews Aerie Pharmaceuticals Inc (AERI) in Light of FDA Agreement

Aerie Pharmaceuticals Inc (NASDAQ:AERI) has created a lot of buzz this morning as shares jumped 56% in pre-market trading following news that the …

Tuesday Morning Pre-Market Insights: Aerie Pharmaceuticals Inc (AERI), Nokia Corporation (ADR) (NOK), Avalanche Biotechnologies Inc (AAVL), Tonix Pharmaceuticals Holding Corp. (TNXP)

Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 56% to $20.75 in pre-market trading after the FDA agreed to allow Aerie to change the …

RBC Capital Maintains Positive View of Aerie Pharmaceuticals Inc Following FDA Agreement to Change Endpoint Range for Rhopressa

RBC Capital analyst Adnan Butt weighed in with some commentary on Aerie Pharmaceuticals Inc (NASDAQ:AERI) following an FDA agreement that the company may change the primary endpoint …

Brean Capital Reiterates Buy on Aerie Pharmaceuticals Inc Following Meeting with Management

In a research report released April 30, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a $24 price …

Analysts Weigh In on Aerie Pharmaceuticals Inc (AERI) as Rhopressa Misses Primary Endpoint

Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares plunged nearly 64% today after the company reported disappointing efficacy results from its first Phase 3 trial for Rhopressa, the company’s lead glaucoma …

Brean Capital Slashes Price Target for Aerie Pharmaceuticals Inc, But Sees 87% Upside for the Stock

In a research report issued Friday, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI), and reduced the price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts